CpG oligodeoxynucleotides (ODNs) strongly activate the immune system after binding to toll-like receptor 9 (TLR9) in lysosome, which demonstrated significant potential in cancer immunotherapy. However, their therapeutic efficacy is limited by drawbacks such as rapid degradation and poor cellular uptake. Although encouraging progress have been made on developing various delivery systems for CpG ODNs, safety risks of the synthetic nanocarriers as well as the deficient CpG ODNs release within lysosome remain big obstacles. Herein, we developed a novel nanovector for lysosome-targeted CpG ODNs delivery and enhanced cancer immunotherapy. Natural glycogen was simply aminated (NH-Gly) through grafting with diethylenetriamine (DETA), which was spherical in shape with diameter of approximately 40 nm. NH-Gly possessed good biocompatibility. Cationic NH-Gly complexed CpG ODNs well and protected them from nuclease digestion. NH-Gly significantly enhanced the cellular uptake of CpG ODNs. Efficient CpG ODNs release was observed in the presence of α-glucosidase that mimicking the environment of lysosome. Consequently, NH-Gly/CpG complexes triggered potent antitumor immunity and effectively inhibit the tumor growth without causing any toxic effect or tissue damages. This work highlights the promise of glycogen for lysosome-targeted on-command delivery of CpG ODNs, which brings new hope for precision cancer immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijbiomac.2023.128536 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Osteogenic CpG Oligodeoxynucleotide, iSN40, Inhibits Osteoclastogenesis in a TLR9-Dependent Manner.
Life (Basel)
November 2024
Department of Agriculture, Graduate School of Science and Technology, Shinshu University, 8304 Minami-minowa, Kami-ina, Nagano 399-4598, Japan.
A CpG oligodeoxynucleotide (CpG-ODN), iSN40, was originally identified as promoting the mineralization and differentiation of osteoblasts, independent of Toll-like receptor 9 (TLR9). Since CpG ODNs are often recognized by TLR9 and inhibit osteoclastogenesis, this study investigated the TLR9 dependence and anti-osteoclastogenic effect of iSN40 to validate its potential as an osteoporosis drug. The murine monocyte/macrophage cell line RAW264.
View Article and Find Full Text PDFPreclinical study of TLR stimulation combined PD-1 antibody enhance the therapeutic effect of microwave ablation on NSCLC.
Clin Transl Oncol
December 2024
Hebei Key Laboratory of Respiratory Critical Care Medicine, The First Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Hebei Institute of Respiratory Diseases, No. 215 Heping West Road, Shijiazhuang, 050000, Hebei, China.
Purpose: The purpose of this study was to investigate the therapeutic efficacy of the combination of microwave ablation (MWA) with immune checkpoints blockade and TLR9 stimulation in the treatment of non-small cell lung cancer (NSCLC) using the C57BL/6 tumor-bearing mice model.
Materials And Methods: Tumor-bearing mice were treated with MWA, programmed cell death protein1 blockade (PD-1) plus MWA (MWA + P), TLR9 agonist CpG ODNs and MWA (MWA + C), PD-1 blockade and CpG ODNs (P + C), MWA plus PD-1 blockade and CpG ODNs (MWA + P + C), or untreated. Survival time was evaluated with the Kaplan-Meyer method comparing survival curves by log-rank test.
Biocompatible DNA hydrogel composed of minimized Takumi-shaped DNA nanostructure exhibits sustained retention after in vivo administration.
J Control Release
January 2025
Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan. Electronic address:
Our previous studies showed that DNA hydrogels containing unmethylated CpG motifs effectively induced antigen-specific immune responses when combined with the appropriate antigens. A potential drawback of existing DNA hydrogels for further applications is the need for many oligodeoxynucleotide (ODN) types. Therefore, in this study, we attempted to optimize and minimize the nanostructured DNA units for DNA hydrogels to reduce the preparation cost, design difficulty, and possible risk of sequence-dependent off-target effects, and prepare DNA hydrogels with sustained retention ability.
View Article and Find Full Text PDFmRNA compartmentalization via multimodule DNA nanostructure assembly augments the immunogenicity and efficacy of cancer mRNA vaccine.
Sci Adv
November 2024
New Cornerstone Science Laboratory, CAS Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, 100190, China.
Article Synopsis
- mRNA vaccines show promise for cancer treatment, but their effectiveness is currently limited by low immune response and inefficient mRNA expression.
- A new approach uses a custom DNA nanostructure called MMDNS, which helps improve mRNA translation by concentrating mRNA and necessary reaction components in specific areas.
- This innovative vaccine design results in a stronger immune response against tumors, helping to inhibit their growth and spread, making it a significant development in cancer immunotherapy.
A novel immunomodulating peptide with potential to complement oligodeoxynucleotide-mediated adjuvanticity in vaccination strategies.
Sci Rep
November 2024
Concept Life Sciences, Edinburgh, Scotland.
Article Synopsis
- Identifying new adjuvants to make vaccines more effective is crucial, with one promising method being the use of TLR9 agonists like CpG ODNs to boost dendritic cell function.
- D-15800, a specific D-peptide isomer, has been found to better stimulate the production of the immune response mediator IL-12p70 and promote differentiation of monocytes into dendritic cells compared to its L-isomer counterpart.
- When combined with TLR9 agonists, D-15800 not only activates immune cells like CD4 T and natural killer cells but also enhances interferon-alpha production, indicating it could significantly improve vaccine outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!